×
About 15,302 results

ALLMedicine™ Hemophilia Center

Research & Reviews  6,637 results

Identification of Zebrafish Ortholog for Human Coagulation Factor IX and its Age-depend...
https://doi.org/10.1111/jth.15365
Journal of Thrombosis and Haemostasis : JTH; Iyer N, Al Qaryoute A et. al.

May 11th, 2021 - Coagulation factor IX (FIX) is a serine protease zymogen involved in the intrinsic blood coagulation pathway, and its deficiency causes Hemophilia B. Zebrafish has three f9 genes, and the ortholog to human F9 is unknown. To identify the zebrafish ...

Identification of a modified coagulation factor X with enhanced activation properties a...
https://doi.org/10.1016/j.bcmd.2021.102570
Blood Cells, Molecules & Diseases; Ebert M, Raquet E et. al.

May 7th, 2021 - Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing a...

Which tests can most effectively indicate the clinical phenotype of paediatric haemophi...
https://doi.org/10.1097/MBC.0000000000001028
Blood Coagulation & Fibrinolysis : an International Journ... Ay Y, Toret E et. al.

May 6th, 2021 - Patients with haemophilia A who have similar FVIII levels show clinical heterogeneity, and 10-15% of patients with severe haemophilia do not have a severe bleeding phenotype. The aim of this study was to assess whether global haemostasis tests, su...

EMICIZUMAB DOSING IN CHILDREN AND ADULTS WITH HEMOPHILIA A: SIMULATING A USER-FRIENDLY ...
https://doi.org/10.1055/a-1499-0030
Thrombosis and Haemostasis; Bukkems L, Fischer K et. al.

May 4th, 2021 - When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient emicizumab maintenance dos...

CAR and TRuC redirected regulatory T cells differ in capacity to control adaptive immun...
https://doi.org/10.1016/j.ymthe.2021.04.034
Molecular Therapy : the Journal of the American Society O... Rana J, Perry DJ et. al.

May 3rd, 2021 - Regulatory T cells (Treg) control immune responses in autoimmune disease, transplantation, and enable antigen-specific tolerance induction in protein replacement therapies. Tregs can exert a broad array of suppressive functions through their T cel...

see more →

Guidelines  59 results

The role of total ankle replacement in patients with hemophilia and end‐stage ankle arthropathy: A review
https://onlinelibrary.wiley.com/doi/10.1111/hae.14196
Haemophilia Sackstein P

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Current practices in hemophilic patients undergoing orthopedic surgery - a systematic review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588779/
Experimental and Therapeutic Medicine; Badulescu OV

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 2nd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 20...

The High Price of Hemophilia
https://www.ashclinicalnews.org/spotlight/feature-articles/high-price-hemophilia/
ASH Clinical News; Lawrence L

Jan 31st, 2020 - An estimated 20,000 people in the U.S. are living with the inherited bleeding disorder hemophilia, and more than 60% of them have moderate or severe hemophilia requiring lifelong treatment with expensive drugs and clotting factors.

Bayer Statement on Voluntary Recall of Two Lots of Kogenate FS Antihemophilic Factor (Recombinant) in the United States
https://www.drugs.com/fda/bayer-statement-voluntary-recall-two-lots-kogenate-fs-antihemophilic-factor-recombinant-united-14291.html

Jul 18th, 2019 - Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemop...

see more →

Drugs  201 results see all →

Clinicaltrials.gov  7,285 results

Identification of Zebrafish Ortholog for Human Coagulation Factor IX and its Age-depend...
https://doi.org/10.1111/jth.15365
Journal of Thrombosis and Haemostasis : JTH; Iyer N, Al Qaryoute A et. al.

May 11th, 2021 - Coagulation factor IX (FIX) is a serine protease zymogen involved in the intrinsic blood coagulation pathway, and its deficiency causes Hemophilia B. Zebrafish has three f9 genes, and the ortholog to human F9 is unknown. To identify the zebrafish ...

Health Costs Over 25 Times Higher for Patients With Hemophilia B
https://www.medscape.com/viewarticle/951014

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

Identification of a modified coagulation factor X with enhanced activation properties a...
https://doi.org/10.1016/j.bcmd.2021.102570
Blood Cells, Molecules & Diseases; Ebert M, Raquet E et. al.

May 7th, 2021 - Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing a...

Which tests can most effectively indicate the clinical phenotype of paediatric haemophi...
https://doi.org/10.1097/MBC.0000000000001028
Blood Coagulation & Fibrinolysis : an International Journ... Ay Y, Toret E et. al.

May 6th, 2021 - Patients with haemophilia A who have similar FVIII levels show clinical heterogeneity, and 10-15% of patients with severe haemophilia do not have a severe bleeding phenotype. The aim of this study was to assess whether global haemostasis tests, su...

EMICIZUMAB DOSING IN CHILDREN AND ADULTS WITH HEMOPHILIA A: SIMULATING A USER-FRIENDLY ...
https://doi.org/10.1055/a-1499-0030
Thrombosis and Haemostasis; Bukkems L, Fischer K et. al.

May 4th, 2021 - When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient emicizumab maintenance dos...

see more →

News  1,101 results

Health Costs Over 25 Times Higher for Patients With Hemophilia B
https://www.medscape.com/viewarticle/951014

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

Bleeding Disorder Diagnoses Delayed by Years in Girls and Women
https://www.medscape.com/viewarticle/947192

Mar 9th, 2021 - Diagnosis of bleeding disorders in girls and women can lag behind diagnosis in boys and men by more than a decade, meaning needless delays in treatment and poor quality of life for many with hemophilia or related conditions. "There is increasing a...

US Operation Warp Speed's Slaoui Joins Newly Formed Drug Developer as Lead Scientist
https://www.medscape.com/viewarticle/945873

Feb 16th, 2021 - (Reuters) - Moncef Slaoui, formerly the chief scientific adviser for the U.S. government's Operation Warp Speed COVID-19 vaccine development program, has joined newly formed Centessa Pharmaceuticals as its chief scientific officer. He will oversee...

Gene Therapy a Potential 'Game Changer' for Hemophilia B
https://www.medscape.com/viewarticle/942762

Dec 17th, 2020 - NEW YORK (Reuters Health) - An investigational gene therapy for hemophilia B substantially increased production of the blood-clotting protein factor IX and reduced the number of bleeding episodes and need for prophylactic therapy in a phase-3 tria...

The role of total ankle replacement in patients with hemophilia and end‐stage ankle arthropathy: A review
https://onlinelibrary.wiley.com/doi/10.1111/hae.14196
Haemophilia Sackstein P

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

see more →

Patient Education  19 results see all →